Key Finding
A 12-week randomized controlled trial is underway to evaluate whether transcutaneous auricular vagus nerve stimulation (taVNS) can reduce body weight in patients with obesity by modulating the microbiota-gut-brain axis, assessed through fMRI, gut microbiota profiling, and serum brain-gut peptides.
Could a gentle electrical treatment applied to your ear help with weight loss? Researchers are investigating exactly that with a technique called transcutaneous auricular vagus nerve stimulation, or taVNS. This non-invasive approach delivers mild electrical stimulation to a specific point on the outer ear — the cymba conchae — to activate the vagus nerve, a major communication highway between your brain and gut.
The study is exploring how taVNS might help people with obesity by influencing what scientists call the microbiota-gut-brain axis. This is the complex relationship between your gut bacteria, digestive system, and brain that plays a surprisingly important role in how your body regulates weight, appetite, stress, and mood.
In this clinical trial, 74 people with obesity will be randomly assigned to receive either real taVNS or a sham (inactive) version for 12 weeks. Researchers will track changes in body weight, BMI, waist and hip measurements, body fat percentage, and visceral fat. They will also measure quality of life, stress levels, mood, eating behaviors, and fatigue. To understand what is happening inside the body, participants will undergo brain imaging (fMRI), gut microbiota testing, and blood tests for gut-brain hormones.
While this is a study protocol — meaning results are not yet available — the research is significant because it takes a whole-body approach to understanding how ear stimulation might produce real, measurable changes in weight and wellbeing. If successful, taVNS could offer a safe, drug-free option for people struggling with obesity who have not found lasting results with conventional approaches.
This research builds on a long tradition in acupuncture of using ear points to influence whole-body health. If you are curious about auricular acupuncture or neuromodulation for weight management, speak with a licensed acupuncturist or integrative medicine practitioner who has experience in this area.
This randomized controlled trial protocol investigates transcutaneous auricular vagus nerve stimulation (taVNS) as a non-pharmacological intervention for obesity, with a focus on microbiota-gut-brain (MGB) axis modulation. A total of 74 patients with obesity will be randomized 1:1 to active taVNS (left cymba conchae) or sham stimulation (helix tail) over 12 weeks. The primary endpoint is percentage change in body weight from baseline. Secondary endpoints include BMI, waist and hip circumference, body fat percentage, and visceral fat area. Validated psychometric instruments — IWQOL-Lite, PSS, HAMD, DEBQ, IPAQ, and FS-14 — will assess quality of life, psychological, and behavioral parameters. Mechanistic endpoints include fMRI-derived neural activity, gut microbiota composition profiling, and serum brain-gut peptides. No efficacy results are yet available as this is a protocol publication. Clinical takeaway: taVNS targeting auricular vagal afferents represents a plausible neuromodulatory strategy for obesity management, and this trial's multimodal mechanistic framework will help clarify gut-brain pathway involvement in treatment response.
Browse our directory of verified licensed practitioners near you.
Find a practitioner →📌 Acupuncture significantly reduced chronic urticaria activity scores and improved dermatology-related quality of life compared to sham acupuncture and waitlist control, performing comparably to Western medicine for symptom control.
📌 77.6% of women with moderate-to-severe menopausal symptoms experienced a clinically relevant reduction in symptoms following a standardized acupuncture protocol, with vocational education level being the most consistent predictor of treatment response.
📌 A five-session standardised acupuncture protocol produced sustained improvements in hot flushes, sweating, and menopausal sleep disturbance that remained largely intact for up to 21 weeks after the final treatment.